Latest Publications

Unsupervised Characterization of the NURTuRE Cohort Reveals Gene Expression and Tissue Remodeling Dynamics along a Synthetic CKD Progression Axis
American Society of Nephrology Kidney Week 2022 | November 2022

A Multi-Omics Approach to IgA Nephropathy Characterization in the NURTuRE Cohort Enables Precision-Based Treatment Approaches
American Society of Nephrology Kidney Week 2022 | November 2022

Updated Interim Results of a Phase 1/2 Study of BION-1301 in Patients with IgA Nephropathy
American Society of Nephrology Kidney Week 2022 | November 2022

Preclinical Efficacy of CHK-336: A First in Class, Liver-Targeted, Small Molecule Inhibitor of Lactate Dehydrogenase for the Treatment of Primary Hyperoxalurias
American Society of Nephrology Kidney Week 2022 | November 2022

Atrasentan for the Treatment of IgA Nephropathy: Interim Results from the AFFINITY Study 
American Society of Nephrology Kidney Week 2022 | November 2022

Single Nuclei RNA-seq Reveals Cell-type Specific Responses to Disease and Enalapril in the gddY Mouse Model of IgAN
American Society of Nephrology Kidney Week 2022 | November 2022

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy – The ALIGN Study
American Society of Nephrology Kidney Week 2022 | November 2022

Atrasentan in Patients with Proteinuric Glomerular Diseases – The AFFINITY Study
American Society of Nephrology Kidney Week 2022 | November 2022

A Phase 1/2 Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults with IgA Nephropathy 
American Society of Nephrology Kidney Week 2022 | November 2022

Defining Cellular Complexity in Human Autosomal Dominant Polycystic Kidney Disease by Multimodal Single Cell Analysis
Nature Communications | October 2022

Atrasentan for the Treatment of IgA Nephropathy: Interim Results from the AFFINITY Study
59th ERA Congress 2022 | May 2022

A Systems Nephrology Framework for the Molecular Classification of Chronic Kidney Disease
59th ERA Congress 2022 | May 2022

Updated Interim Results of a Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of BION-1301 in Patients with IgA Nephropathy
59th ERA Congress 2022 | May 2022

Selective Endothelin A Receptor Antagonist Atrasentan Attenuates Mesangial Cell Injury, Proteinuria and Intra-Renal Proliferative, Inflammatory and Fibrotic Transcriptional Networks in a Rat Model of Mesangioproliferative Glomerulonephritis
59th ERA Congress 2022 | May 2022

A Phase 1/2, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults with IgA Nephropathy
59th ERA Congress 2022 | May 2022

Neutralization of APRIL with BION-1301: A Targeted, Potentially Disease-Modifying Approach to IgA Nephropathy
4th Chronic Kidney Disease Drug Development Summit | March 2022

AFFINITY: A Phase 2 Basket Trial to Study the Safety and Efficacy of Atrasentan in Multiple Proteinuric Diseases
4th Chronic Kidney Disease Drug Development Summit | March 2022

Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study)
ISN World Congress of Nephrology 2022 | February 2022

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy (The ALIGN Study)
ISN World Congress of Nephrology 2022 | February 2022

Pharmacodynamic and Clinical Responses to BION-1301 in Patients with IgA Nephropathy: Initial Results of a Phase 1/2 Trial (Encore)
ISN World Congress of Nephrology 2022 | February 2022

ADU-CL-19: a Phase 1/2, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy
ISN World Congress of Nephrology 2022 | February 2022

atrasentan Publications

Single Nuclei RNA-seq Reveals Cell-type Specific Responses to Disease and Enalapril in the gddY Mouse Model of IgAN
American Society of Nephrology Kidney Week 2022 | November 2022

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy – The ALIGN Study
American Society of Nephrology Kidney Week 2022 | November 2022

Atrasentan for the Treatment of IgA Nephropathy: Interim Results from the AFFINITY Study 
American Society of Nephrology Kidney Week 2022 | November 2022

Atrasentan in Patients with Proteinuric Glomerular Diseases – The AFFINITY Study
American Society of Nephrology Kidney Week 2022 | November 2022

Atrasentan for the Treatment of IgA Nephropathy: Interim Results from the AFFINITY Study
59th ERA Congress 2022 | May 2022

Selective Endothelin A Receptor Antagonist Atrasentan Attenuates Mesangial Cell Injury, Proteinuria and Intra-Renal Proliferative, Inflammatory and Fibrotic Transcriptional Networks in a Rat Model of Mesangioproliferative Glomerulonephritis
59th ERA Congress 2022 | May 2022

AFFINITY: A Phase 2 Basket Trial to Study the Safety and Efficacy of Atrasentan in Multiple Proteinuric Diseases
4th Chronic Kidney Disease Drug Development Summit | March 2022

Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study)
ISN World Congress of Nephrology 2022 | February 2022

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy (The ALIGN Study)
ISN World Congress of Nephrology 2022 | February 2022

Atrasentan Exhibits a Consistent, Predictable Pharmacokinetic Profile Among Healthy Asian Adults 
American Society of Nephrology Kidney Week 2021 | November 2021

Precision Medicine Approach Identifies Patients with IgA nephropathy at Risk for Progression Using Endothelin Activation Signatures
American Society of Nephrology Kidney Week 2021 | November 2021

Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy (The ALIGN Study)
American Society of Nephrology Kidney Week 2021 | November 2021

Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study)
American Society of Nephrology Kidney Week 2021 | November 2021

A Central Role of Endothelin A (ETA) Receptor Activation in Mesangial Cell–Podocyte Crosstalk In IgA Nephropathy and Other Mesangio-Proliferative Glomerulopathies
13th International Podocyte Conference | July 2021

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy (The ALIGN Study)
58th European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress | June 2021

Selective ETA Antagonist Atrasentan, Rapidly Reduces Albuminuria and Downregulates Intra-renal Pro-Inflammatory and Pro-Fibrotic Transcriptional Networks in the g-ddY Mouse Model of Spontaneous IgA Nephropathy
ISN World Congress of Nephrology 2021 | April 2021

Human Renal Mesangial Cell Activation Induced by Endothelin-1 or IgA Nephropathy Patient Immune Derived Complexes is Blocked by Selective ETA Antagonist Atrasentan
ISN World Congress of Nephrology 2021 | April 2021

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy
(The ALIGN Study)
ISN World Congress of Nephrology 2021 | April 2021

Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study)
ISN World Congress of Nephrology 2021 | April 2021

A Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study of Atrasentan in Patients with IgA Nephropathy (The ALIGN Study)
American Society of Nephrology Kidney Week 2020 Reimagined | October 2020

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
The Lancet | April 2019

SONAR propels endothelin A receptor antagonists to success
The Lancet | April 2019

A turning point for chronic kidney disease in diabetes
The Lancet | April 2019

Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight
Diabetes Obes Metab. | February 2018

The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy
Journal of the American Society of Nephrology | 2014

Endothelin and Endothelin Antagonists in Chronic Kidney Disease
Kidney Int. | November 2014

BION-1301 Publications

Updated Interim Results of a Phase 1/2 Study of BION-1301 in Patients with IgA Nephropathy
American Society of Nephrology Kidney Week 2022 | November 2022

A Phase 1/2 Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults with IgA Nephropathy 
American Society of Nephrology Kidney Week 2022 | November 2022

Updated Interim Results of a Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of BION-1301 in Patients with IgA Nephropathy
59th ERA Congress 2022 | May 2022

A Phase 1/2, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults with IgA Nephropathy
59th ERA Congress 2022 | May 2022

Neutralization of APRIL with BION-1301: A Targeted, Potentially Disease-Modifying Approach to IgA Nephropathy
4th Chronic Kidney Disease Drug Development Summit | March 2022

Pharmacodynamic and Clinical Responses to BION-1301 in Patients with IgA Nephropathy: Initial Results of a Phase 1/2 Trial (Encore)
ISN World Congress of Nephrology 2022 | February 2022

ADU-CL-19: a Phase 1/2, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy
ISN World Congress of Nephrology 2022 | February 2022

Pharmacodynamic and Clinical Responses to BION-1301 in Patients with IgA Nephropathy: Initial Results of a Ph1/2 Trial
American Society of Nephrology Kidney Week 2021 | November 2021

A Phase 1/2, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy
American Society of Nephrology Kidney Week 2021 | November 2021

Interim Results of Phase 1 and 2 Trials to Investigate the Safety, Tolerability, Pharmacodynamics and Clinical Activity of BION-1301 in Patients with IgA Nephropathy
58th European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress | June 2021

ADU-CL-19 A Phase 1/2, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults with IgA Nephropathy
58th European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress | June 2021

A Phase 1, Open Label, Randomized, Single Dose, Parallel Group Safety and Bioavailability Study of BION-1301 Administered by Intravenous (IV) and Subcutaneous (SC) Routes
ISN World Congress of Nephrology 2021 | April 2021

Results of a Phase 1 Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers (Encore)
American Society of Nephrology Kidney Week 2020 Reimagined | October 2020

Results of a Phase 1 Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers (Encore)
Asian Pacific Congress of Nephrology | October 2020

Results of a Phase 1 Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers
European Renal Association – European Dialysis and Transplant Association | June 2020

BION-1301, a Fully Blocking Antibody Targeting APRIL for the Treatment of IgA Nephropathy: Assessment of Safety, Toxicokinetics and Pharmacodynamics in Long-Term Nonclinical Studies
European Renal Association – European Dialysis and Transplant Association | June 2020

Nonclinical Safety and PK/PD of BION-1301, a Fully Blocking Antibody Targeting A PRoliferation Inducing Ligand (APRIL) for the Treatment of IgA Nephropathy
American Society of Nephrology Kidney Week | November 2019

BION-1301: a Novel fully Blocking APRIL Antibody for the Treatment of IgA Nephropathy
American Society of Nephrology | October 2018

CHK-336 Publications

Preclinical Efficacy of CHK-336: A First in Class, Liver-Targeted, Small Molecule Inhibitor of Lactate Dehydrogenase for the Treatment of Primary Hyperoxalurias
American Society of Nephrology Kidney Week 2022 | November 2022

Discovery & Characterization of CHK-336: A Liver-Targeted Small Molecule Inhibitor of Lactate Dehydrogenase A (LDHA) for the Treatment of Primary Hyperoxaluria (PH)
Rare & Genetic Kidney Disease Drug Development | December 2021

Discovery of CHK-336: A First-in-Class, Liver-Targeted, Small Molecule Inhibitor of Lactate Dehydrogenase for the Treatment of Hyperoxaluria
ISN World Congress of Nephrology 2021 | April 2021

Discovery of CHK-336: A First-in-Class, Liver-Targeted, Small Molecule Inhibitor of Lactate Dehydrogenase for the Treatment of Primary Hyperoxaluria
American Society of Nephrology Kidney Week 2020 Reimagined | October 2020

Research and Discovery Publications

Unsupervised Characterization of the NURTuRE Cohort Reveals Gene Expression and Tissue Remodeling Dynamics along a Synthetic CKD Progression Axis
American Society of Nephrology Kidney Week 2022 | November 2022

A Multi-Omics Approach to IgA Nephropathy Characterization in the NURTuRE Cohort Enables Precision-Based Treatment Approaches
American Society of Nephrology Kidney Week 2022 | November 2022

Single Nuclei RNA-seq Reveals Cell-type Specific Responses to Disease and Enalapril in the gddY Mouse Model of IgAN
American Society of Nephrology Kidney Week 2022 | November 2022

Defining Cellular Complexity in Human Autosomal Dominant Polycystic Kidney Disease by Multimodal Single Cell Analysis
Nature Communications | October 2022

A Systems Nephrology Framework for the Molecular Classification of Chronic Kidney Disease
59th ERA Congress 2022 | May 2022

Dual Glycolate Oxidase/Lactate Dehydrogenase A Inhibitors for Primary Hyperoxaluria
ACS Medicinal Chemistry Letters | May 2021

Single Cell Transcriptomic Analysis to Define Cellular Heterogeneity in Human ADPKD
American Society of Nephrology Kidney Week 2020 Reimagined | October 2020